Saijo N - Search Results

1

Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.

Sakai K, Arao T, Shimoyama T, Murofushi K, Sekijima M, Kaji N, Tamura T, Saijo N, Nishio K. Sakai K, et al. Among authors: saijo n. FASEB J. 2006 Feb;20(2):311-3. doi: 10.1096/fj.05-4034fje. Epub 2005 Dec 22. FASEB J. 2006. PMID: 16373402

2

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Arao T, et al. Among authors: saijo n. Cancer Res. 2004 Dec 15;64(24):9101-4. doi: 10.1158/0008-5472.CAN-04-2360. Cancer Res. 2004. PMID: 15604279

3

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.

Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K. Koizumi F, et al. Among authors: saijo n. Int J Cancer. 2005 Aug 10;116(1):36-44. doi: 10.1002/ijc.20985. Int J Cancer. 2005. PMID: 15761868

4

In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.

Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. Sakai K, et al. Among authors: saijo n. Biochem J. 2006 Aug 1;397(3):537-43. doi: 10.1042/BJ20051962. Biochem J. 2006. PMID: 16623663 Free PMC article.

5

AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.

Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N, Nishio K. Takeda M, et al. Among authors: saijo n. Clin Cancer Res. 2007 May 15;13(10):3051-7. doi: 10.1158/1078-0432.CCR-06-2743. Clin Cancer Res. 2007. PMID: 17505008

6

Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.

Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. Sakai K, et al. Among authors: saijo n. Cancer Sci. 2007 Sep;98(9):1498-503. doi: 10.1111/j.1349-7006.2007.00553.x. Epub 2007 Jul 11. Cancer Sci. 2007. PMID: 17627612 Free PMC article.

7

Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.

Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K. Koizumi F, et al. Among authors: saijo n. Int J Cancer. 2004 Jan 20;108(3):464-72. doi: 10.1002/ijc.11539. Int J Cancer. 2004. PMID: 14648715

8

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K. Taguchi F, et al. Among authors: saijo n. Cancer Sci. 2004 Dec;95(12):984-9. doi: 10.1111/j.1349-7006.2004.tb03187.x. Cancer Sci. 2004. PMID: 15596048 Free PMC article.

9

Translational studies for target-based drugs.

Nishio K, Arao T, Shimoyama T, Fujiwara Y, Tamura T, Saijo N. Nishio K, et al. Among authors: saijo n. Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:90-3. doi: 10.1007/s00280-005-0104-6. Cancer Chemother Pharmacol. 2005. PMID: 16273363 Review.

10

Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.

Ando K, Ohmori T, Inoue F, Kadofuku T, Hosaka T, Ishida H, Shirai T, Okuda K, Hirose T, Horichi N, Nishio K, Saijo N, Adachi M, Kuroki T. Ando K, et al. Among authors: saijo n. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8872-9. doi: 10.1158/1078-0432.CCR-05-0811. Clin Cancer Res. 2005. PMID: 16361577

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

756 results

Search Page

Filters